Serological changes following a single intravenous Corynebacterium parvum injection in the rat

Summary Changes in circulating levels of immunoglobulins (IgM and IgG), C3, acute-phase reactants, total protein, albumin, iron, and indicators of hepatic and renal function were monitored for up to 3 weeks after a single IV Corynebacterium parvum (C. parvum) injection. In addition to a marked increase in immunoglobulins, there was also evidence of complement activation and of tissue injury typified by a classic acute phase response in levels of ₂-macroglobulin and fibrinogen.A fall in total protein and albumin levels was observed during the first 2 days after C. parvum administration, and significant decreases in serum iron also occurred within the first 4 days. In contrast, increases in serum transaminase and alkaline phosphatase activity were consistent with hepatic injury. Furthermore, raised levels of urea and creatinine suggested mild impairment of renal function.These results indicate the need for serial, serological monitoring of immunological, hepatic and renal function during systemic immunotherapy with C. parvum.     

Disseminated intravascular coagulation and the balance between blood coagulation and fibrinolysis

The dynamic haemostatic balance between blood coagulation and fibrinolysis and its influence on the development of disseminated intravascular coagulation are described. The effects of heparin and antithrombin-III are illustrated by clinical cases.     

Splenic suppressor macrophages induced in mice by injection of Corynebacterium parvum.

Spleen cells from C57BL/6N mice injected with killed Corynebacterium parvum (CP) had a marked growth inhibitory effect on the in vitro proliferation of RBL-5 murine lymphoma cells. It was most marked 12 to 14 days after injection and was usually no longer detectable later than 21 days. It could be demonstrated at effector cell to target ratios between 20:1 and 5:1 at which normal spleen cells had a growth-promoting effect. Addition of CP to an in vitro mixture of spleen cells and tumor cells augmented the inhibitory effect of spleen cells from CP-injected mice although it conferred no inhibitory potential on normal spleen cells. Growth inhibiton by CP spleen cells was not mediated by T cells and various depletion experiments suggested that the effector cells of the phenomenon were macrophages. Spleen cells of CP-injected mice also showed strongly depressed responses to the T cell mitogens PHA and Con A and suppressed the mitogen responses of syngeneic normal spleen cells. The characteristics of the suppressor cells mediating this effect appeared to be very similar to those inhibiting lymphoma cell growth. The responses to LPS were also strongly suppressed in mice injected with 2.1 mg of CP. However, after injection of one-tenth of the dose a relative sparing of the LPS response was noted, whereas the PHA response was still suppressed.     

Disseminated intravascular coagulation in acute monoblastic leukemia: response to heparin therapy.

A 27-year-old man with acute monoblastic leukemia had clinical and laboratory evidence of disseminated intravascular coagulation (DIC), which was exacerbated by induction chemotherapy. Heparin therapy, adjusted according to the patient''s clinical status and the results of coagulation studies, rapidly controlled the manifestations of DIC.     

Babesia argentina: Disseminated intravascular coagulation in acute infections in splenectomized calves

The pathology of severe Babesia argentina infections in splenectomized calves was studied. The calves were infected by intravenous inoculation of 10⁹–10¹⁰B. argentina and given 0.1 mg/kg betamethasone to enhance the parasitemia. Hematological changes observed during detailed studies of the course of infection in eight calves, three of which subsequently died, included thrombocytopenia, leucopenia, and reduced fibrinogen levels. The prothrombin time and partial thromboplastin time were prolonged in all three calves tested, and pathological levels of fibrinogen degradation products were detected in both of two calves tested. Massive pulmonary edema was a constant finding at autopsy of 24 fatal cases. Histopathological examination revealed widespread fibrin thrombi in capillaries and larger vessels of lung, in capillaries of renal glomeruli, and in hepatic sinusoids. The findings established the occurrence of disseminated intravascular coagulation in the acute infections studied.     

Rejection of tumor metastases in Fischer 344 rats following the administration of killed Corynebacterium parvum

Summary Fischer 344 rats received subcutaneous grafts of syngeneic 13762 mammary adenocarcinoma cells. Thereafter, at 20 days, each animal of a group received either daily (×2) permeating intratumor injections of killed Corynebacterium parvum (1.0 mg) saline, and weekly (×4) intravenous (i.v.) or intraperitoneal (i.p.) C. parvum or saline. In addition, a group each (4 groups) of rats were treated with surgical extirpation of the growing tumor nodule and i.v. and i.p. C. parvum or saline administered at weekly (×4) intervals. The results revealed that following intratumor injection of C. parvum there was rejection of tumor by all animals which exhibited long-term survival for 29 months (intratumor saline: 0% survival). The groups of rats treated with surgical extirpation of the tumor and parenteral administration of C. parvum exhibited 70–75% survival for 20 months (saline treated: 20–35% survival). The surviving animals exhibited tumor-specific protection to subsequent tumor cell challenges. Macrophages separated from the lung, peritoneum, and spleen of rats from the intratumor C. parvum group exhibited respectively, 46.2%, 62.9%, and 29.4% cytotoxicity towards target 13762 tumor cells as measured by ⁵¹ Cr release. Similar studies using macrophages from the group treated with surgery and parenteral C. parvum revealed similar tumor cytotoxicity (pulmonary: 49.2%; peritoneal: 65.7%; spleen: 34.4%). The splenic lymphocytes from the intratumor and parenteral C. parvum groups exhibited, respectively, 16.9% and 14.7% ⁵¹ Cr release following incubation with target tumor cells.This study was supported in part by Grant No. CA18582-01 from the National Cancer Institute